# Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein Vaccine

> **NCT01880411** · PHASE1 · UNKNOWN · sponsor: **HealthBanks Biotech Co., Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- Cervical Intraepithelial Neoplasia

## Interventions

- **BIOLOGICAL:** PEK Fusion Protein Vaccine

## Key facts

- **NCT ID:** NCT01880411
- **Lead sponsor:** HealthBanks Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-06
- **Primary completion:** 2014-01
- **Final completion:** 2014-06
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2013-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01880411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01880411, "Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01880411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*